Casgevy, the first CRISPR-based therapy, treats sickle cell disease and beta-thalassemia by editing faulty genes in stem cells. It targets severe cases, offering a potential cure by reactivating fetal hemoglobin. Patients undergo stem cell collection, lab editing, and reinfusion, reducing painful crises and transfusion dependence for eligible adults and adolescents.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends